Document is current

Article History

Received: 2 January 2024

Accepted: 6 June 2024

First Online: 24 June 2024

Declarations

:

: The study was approved by the Mass General Institutional Review Board (IRB) which served as the central IRB for the TARGET study.

: Not applicable.

: KPL receives royalties from UpToDate on chapters related to rheumatoid arthritis and coronary artery disease and has been a consultant for UCB. PMR has received compensation for editorial work from the American Heart Association. JTG has been a consultant for AbbVie, Pfizer, Eli Lilly and Company, Bristol Meyers Squibb, Gilead, Novartis in the last 3 years and received an unrestricted grant from Pfizer. Over the past 36 months, PMR received investigator- initiated research grant support from Novartis, Kowa, Amarin, Pfizer, Esperion, NHLBI, NCI and Operation Warp Speed; served as a consultant to Corvidia, Novartis, Flame, Agepha, Alynlam, IQVIA, R-Pharma, Horizon Therapeutics, Inflazome, AstraZeneca, Jannsen, Civi Biopharm, SOCAR, Novo Nordisk, Health Outlook, Omeicos, the Baim Institute, Boehringer-Ingelheim, Montai Health, Cardiol Therapeutics, the Peter Munk Institute (University of Toronto); and the Foundation Leducq (Paris, FR); and received non-monetary research support from the Pfizer Bristol Myers Squibb Alliance and from Quidel, Inc to conduct federally funded COVID-19 research. PMR is also listed as a co-inventor on patents held by his institution, the Brigham and Women’s Hospital. None of these conflicts relate to the current manuscript. AT receives research support through his institution from Lung Biotechnologies for unrelated work. JMB has nothing to declare. DHS receives research support through his institution from CorEvitas, Janssen, and Novartis. He receives royalties from UpToDate on chapters unrelated to this work.